Wockhardt Ltd — Board/Management Information 2026

May 4, 2026

WOCKHARDT LIFE WiNS

Ref. No.: WOCK/SEC/SE/2026-27/009

4th May, 2026

| BSE Limited
Corporate Relations Department
P J Towers, Dalal Street, Mumbai - 400 001
Scrip Code: 532300 | National Stock Exchange of India Limited
Exchange Plaza,Bandra Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: WOCKPHARMA |
| --- | --- |

Dear Sir/ Madam,

Subject: Change in Senior Management Personnel ('SMP')

In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 4th May, 2026, inter-alia, has identified and designated Ms. Annapurna Das, President (India Business & Emerging Markets (NCE)), Mr. Om Narayan, Senior Vice President (Biotech Research Centre) and Mr. Sunil Soni, Senior Vice President (Biotechnology) as Senior Management Personnel of the Company.

Details with respect to the said designated SMPs as required under Regulation 30(6) read with Para A(7) of Part A of Schedule III of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure I, II and III respectively.

The above information is also available on the website of the Company i.e https://www.wockhardt.com.

Kindly take the same on record.

For Wockhardt Limited

Rashmi Dinesh
Mamtura
Digitally signed by
Rashmi Dinesh Mamtura
Date: 2026.05.04 18:21:00
+05'30'

Rashmi Mamtura
Company Secretary
Encl: a/a

WOCKHARDT LIMITED • Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Mumbai-400051, India • T: 91-22-26534444

Regd. Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhajinagar-431006, India • T: 91-240-6694444 • F: 91-240-2489219

www.wockhardt.com • CIN: L24230MH1999PLC120720

---

WOCKHARDT LIFE WINS

Annexure I

The details required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No.	Particulars	Details of Ms. Annapurna Das
1	Reason for change viz. appointment, resignation,—removal, death or otherwise	The Board of Directors of the Company has identified and designated Ms. Annapurna Das, President (India Business & Emerging Markets (NCE)) as the Senior Management Personnel of the Company.
2	Date of appointment/cessation (as applicable) & term of appointment	May 4, 2026
Term: Full-time employment
3	Brief profile (in case of appointment);	Ms. Annapurna Das, aged 52 years, holds a B.Tech (Chemical Engineering) degree from BIT Sindri and M.B.A. (Marketing) (Post Graduation) from Madurai Kamraj University. She is a seasoned pharmaceutical leader with over 26 years of experience across general management, strategy, and commercial operations in India and Asia.

Prior to joining Wockhardt, she served as Vice President and General Manager at Takeda India, where she led the India and Sri Lanka business for super-specialty portfolio across oncology, biologics, gastroenterology, and rare diseases. Earlier, she was Managing Director and Area Head for India and Southeast Asia at Miltenyi Biotec, where she established and scaled cell and gene therapy operations in the region. She also held senior leadership roles at Sanofi, including non-independent Board member and Head of Asia (Vaccines). She has also held strategy and business development roles at MSD, GSK, Pfizer, and Organon. She brings strong leadership, deep expertise and proven track record in driving growth and business transformation across diverse markets. |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | Not Applicable. |
| 5 | Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/ CML/2018/24, both dated 20 June 2018 | Not Applicable. |

WOCKHARDT LIMITED • Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Mumbai-400051, India • T: 91-22-26534444

Regd. Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhajinagar-431006, India • T: 91-240-6694444 • F: 91-240-2489219

www.wockhardt.com • CIN: L24230MH1999PLC120720

---

WOCKHARDT LIFE WINS

Annexure II

The details required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No.	Particulars	Details of Mr. Om Narayan
1	Reason for change viz. appointment, re-appointment—resignation, removal, death or otherwise	The Board of Directors of the Company has identified and designated Mr. Om Narayan, as Senior Vice President (Biotech Research Centre) as Senior Management Personnel of the Company.
2	Date of appointment/re-appointment/cessation (as applicable) & term of appointment	May 4, 2026
Term: Full-time employment
3	Brief profile (in case of appointment);	Mr. Om Narayan, aged 52 years, holds a Master's degree in Biotechnology from Goa University (1995). He brings nearly three decades of diverse experience across R&D, manufacturing, biosimilars, and vaccines. Over the years, he has held senior leadership roles at Piramal Pharmaceuticals, Kashiv BioSciences, Mylan (Viatris), Biological E Limited, Intas Biopharma, Avesthagen, Serum Institute of India, and Wockhardt Research Center, contributing to multiple global biosimilar and vaccine approvals and facility setups.
4	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated 20 June 2018	Not Applicable.

WOCKHARDT LIMITED • Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Mumbai-400051, India • T: 91-22-26534444

Regd. Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhajinagar-431006, India • T: 91-240-6694444 • F: 91-240-2489219

www.wockhardt.com • CIN: L24230MH1999PLC120720

---

WOCKHARDT LIFE WINS

Annexure III

The details required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No.	Particulars	Details of Mr. Sunil Soni
1	Reason for change viz. appointment, resignation, removal, death or otherwise	The Board of Directors of the Company has identified and designated Mr. Sunil Soni, Senior Vice President (Biotechnology) as the Senior Management Personnel of the Company.
2	Date of appointment/cessation (as applicable) & term of appointment	May 4, 2026
Term: Full-time employment
3	Brief profile (in case of appointment);	Mr. Sunil Soni, aged 54 years, holds a Master's degree in Bio-Chemical Engineering & Biotechnology from IIT Delhi (1993). He brings with him nearly three decades of rich experience in Projects, Manufacturing Operations, Process Development and scale up & Process Improvement Initiatives in API & Biotech industries. Over the years, he has held senior leadership roles at Biological E., Serum Institute of India, Concord Biotech Ltd, Gujarat Themis Biosyn Ltd, Wockhardt Ltd. and Lupin Chemicals Ltd etc. contributing in Process Operations, Equipment design operations ,Manufacturing Operations, Production Planning & Inventory Control, Projects & Commissioning.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated 20 June 2018	Not Applicable.

WOCKHARDT LIMITED • Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Mumbai-400051, India • T: 91-22-26534444

Regd. Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhajinagar-431006, India • T: 91-240-6694444 • F: 91-240-2489219

www.wockhardt.com • CIN: L24230MH1999PLC120720